Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: A prospective parallel placebo-controlled multicentre study

International Journal of Cardiology

Volumn 68, Issue 2, 1999, Pages 187-196

  Capucci, Alessandro ^a   Villani, Giovanni Quinto ^a   Aschieri, Daniela ^a   Piepoli, Massimo ^a  

^a GENERAL HOSPITAL   (Italy)

Author keywords

Antiarrythmic drugs; Atrial fibrillation; Class IC drugs; Digitalis; Propafenone; Quinidine

Indexed keywords

DIGITALIS; PROPAFENONE; QUINIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DIGITALIS GLYCOSIDES; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPAFENONE; PROSPECTIVE STUDIES; QUINIDINE; SAFETY; TREATMENT OUTCOME;

EID: 0033611744     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00363-5     Document Type: Article

References (34)

1. Kannel W.B., Abbot R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. New Engl J Med. 306:1982;1018-1022.
2. Wolf P.A., Abbot R., Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 22:1991;983-988.
3. Anderson J.L., Gilbert E.M., Alpert B.L.et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patiets initially tolerating antiarrhythmic therapy. A multicentre, double-blind, croos-over study of flecainide and placebo with transtelephonic monitoring. Circulation. 80:1989;1557-1559.
4. Lau C.P., Leung W.H., Wong C.K.et al. A randomized double-blind cross over study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J. 124:1992;645-650.
5. Antamnn E.M., Beamer A., Cantillon C.et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged approach with new antiarrhythmic drugs. J Am Coll Cardiol. 15:1990;698-707.
6. Reinold S.C., Cantillon C., Friedman P.L.et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 72:1993;558-562.
7. Donovan K.D., Power B.M., Hockings B.E.et al. Intravenous flecainide versus amiodarone for recent onset atrial fibrillation. Am J Cardiol. 75:1995;693-697.
8. Bianconi M., Boccadamo R., Pappalardo A., Gentili C., Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol. 64:1989;335-338.
9. Borgeat A., Goy J.J., Maendly R., Kaufmann U., Grbic M., Sigwart U. Flecainide vs. quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 58:1986;496-498.
10. Kerin N.Z., Ausari-Leesar M., Faitel K.et al. The effectiveness and safeness of simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation. Am Heart J. 125:1993;1017-1021.
11. Kingma J.H., Suttorp M.J. Acute pharmacologic conversion fo atrial fibrillation and flutter: the role of flecainide, propafenone and verapamil. Am J Cardiol. 70(Suppl. A):1992;56A-561.
12. Capucci A., Lenzi T., Boriani G., Trisolino G., Binetti N., Cavazza M., Fontana G., Magnani B. Effectiveness of loading oral flecainide for converting recent onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 70:1992;69-72.
13. Capucci A., Boriani G., Rubino I., Della Casa S., Sanguinetti M., Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol. 43:1994;305-311.
14. Boriani G., Biffi M., Capucci A.et al. Oral propafenon to convert recent onset atrial fibrillation in patients with and without underlying heart disease. Ann Intern Med. 126:1997;621-625.
15. Boriani G., Capucci A., Lenzi T.et al. Propafenone for conversion of recent onset atrial fibrillation. Chest. 108:1995;355-358.
16. Murdock C.J., Kyles A.E., Yeung-Lai-Wah J.A., Qi A., Vorderbrugge S., Kerr C.R. Atrial flutter in patient treated for atrial fibrillation with propafenone. Am J Cardiol. 66:1990;755-757.
17. Feld G.K., Chen P.S., Nicod P., Fleck R.P., Mezer D. Atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol. 66:1990;378-384.
18. Marcus F.I. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol. 66:1990;366-371.
19. Botto G.L., Bonini W., Broffoni T.et al. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. PACE. 17(Pt. II):1994;2114-2117.
20. Randazzo D.N., Schuritzen P., Stein E.et al. Flecainide induced atrial tachycardia with 1:1 ventricular conduction during exercise testing. PACE. 17:1994;1509-1514.
21. Falk R.H. Flecainide induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med. 111:1989;107-111.
22. Ashan A., Aldridge R., Bowes R.et al. 1:1 atrio-ventricular conduction in atrial flutter with digoxin and flecainide. Int J Cardiol. 39:1993;88-90.
23. Falk R.H. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 117:1992;141-150.
24. Sokolow M. The present status of therapy on cardiac arrhythmias with quinidine. Am Heart J. 42:1951;771-797.
25. Gold H. Quinidine in disorders of the heart. New York: Paul B. Hoeber, 1990:115.
26. Capucci A., Boriani G., Marchesini B., Strocchi E., Tomasi L., Balducelli M., Frabetti L., Ambrosioni E., Magnani B. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. Cardiovascular Drugs Ther. 4:1990;281-287.
27. Schiller N.B., Shah P.M., Crawford M.et al. Recommandations regarding quantitation of the left ventricle by two dimension echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on quantification of two-dimensional Echocardiograms. J Am Soc Echo. 2:1989;358-367.
28. Murgatroyd FD, Camm AJ. Sinus rhythm, the autonomic nervous system and quality of life. In: Kingma JH, et al., editors. Atrial fibrillation: a treatable disease? Netherlands: Kluwer Academy Publisher, 1992:195-210.
29. Bialy D., Lehmann M.H., Schumacher D.N.et al. Hospitalisation for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol. 19(Abstract):1992;41A.
30. Kerr C.R., Klein G.J., Axelson J.E., Cooper J.C. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol. 61:1988;914-916.
31. Channer K.S., Papouchado M., James M.A.et al. Towards improved control of atrial fibrillation. Eur Heart J. 8:1987;141-147.
32. Falk R.H., Knowlton A.A., Bemard S.A., Gotlieb N.E., Battinelli N.J. Digoxin for converting recent onset atrial fibrillation to sinus rhythm. A randomized double blind trial. Ann Intern Med. 106:1987;503-506.
33. Weiner P., Bassan M.M., Jarchovsky J., Iusim S., Plavnick L. Clinical course of acute atrial fibrillation treated with rapid digitalization. Am Heart J. 105:1983;223-230.
34. Laupacis A., Albers G., Dunn M., Feinberg W. Antithtrombotic therapy in atrial fibrillation. Chest. 102(Suppl. 4):1992;426-433.